HCS Pharma is expanding its BIOMIMESYS® 3D cell culture product range with BIOMIMESYS® Brain, a system for culturing neuronal cells that reproduces the physiological conditions of the brain's extracellular matrix. BIOMIMESYS® technology facilitates 3D cell culture using a microenvironment based on hyaluronic acid and other components naturally present in tissues. BIOMIMESYS® Brain is available to assist with in vitro testing for the pharmaceutical and cosmetics industries to help reduce animal testing. HCS Pharma also offers developing cell culture protocols for specific cell types using its BIOMIMESYS® technology.

1. HCS Pharma – Siège de Lille
Biocentre Fleming Bat A
250 rue Salvador Allende
59120 LOOS
BIOMIMESYS®
is a registered trademark
of HCS Pharma
+33 769 999 137
www.biomimesys.com
hello@biomimesys.com
HCS Pharma extends its 3D cell culture range BIOMIMESYS®
with BIOMIMESYS® Brain
Following the success of BIOMIMESYS® range of products, which accurately and
physiologically reproduces the microenvironment of liver, adipose and cancerous tissues,
HCS Pharma is expanding its product range with BIOMIMESYS® Brain, an exclusive and
innovative system for the 3D cell culture of neuronal cells.
BIOMIMESYS® technology, provided “ready-to-use”, is easy to handle for in vitro testing. It
reproduces physiological conditions thanks to a microenvironment based on Hyaluronic Acid, a product
naturally present in the extracellular matrix. BIOMIMESYS® Brain includes in particular collagen IV and
a cationic biopolymer that promotes the long-term culture of neural cells. In addition, its specific
Young's modulus makes its rigidity similar to that of the cerebral extracellular matrix.
All the features of BIOMIMESYS® Brain and the first validation tests are available on
https://biomimesys.com/products/biomimesys-brain/
Today, in vitro tests are a critical step in the development of new drugs for the pharmaceutical and
dermo-cosmetic industries. They make it possible to validate the efficacy of a molecule and test its
toxicity well before the costly phases of clinical testing. They also help to reduce or even replace the
use of animals in preclinical tests. However, these tests are still often performed with 2D cell culture
systems, which are not close enough to the human tissues to give predictive results. The transition to
3D cell culture tools is now necessary for research and industry. BIOMIMESYS® technology facilitates
this transition by reproducing the cellular microenvironment, as close as possible to biological reality.
Several other products are available:
• BIOMIMESYS® Liver : https://biomimesys.com/products/biomimesys-liver/
• BIOMIMESYS® Adipose Tissue : https://biomimesys.com/products/biomimesys-adipose-tissue/
• BIOMIMESYS® Oncology: https://biomimesys.com/products/biomimesys-oncology/
To assist its customers in the use of BIOMIMESYS® technology, HCS Pharma also proposes to develop
cell culture protocols in this environment for specific cell types, on request. BIOMIMESYS® technology
is protected by an exclusive patent held by HCS Pharma.
HCS Pharma
HCS Pharma is a biotechnology start-up located in Lille and Rennes, which offers research and
development services to companies in the pharmaceutical, dermo-cosmetic and food industries. Its
expertise: the development of new tests for in vitro pharmacology and their use in medium/high
throughput screening, using the innovative high throughput cellular imaging technology called High
Content Screening (HCS) and its new 3D culture technology BIOMIMESYS®.
Contact information
Nathalie MAUBON / CEO / nathalie.maubon@hcs-pharma.com / +33 (0)769 999 137